FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on …
MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices The availability of larger quantities …
The Multidisciplinary Association for Psychedelic Studies (MAPS) and Synergetic Press are breathing new life into a classic book that details the work of an underground psychedelic-assisted therapy trailblazer. …
Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be …
We encourage you to read and follow maps.org/safety for detailed information regardingMAPS Code of Ethics for Psychedelic Psychotherapyand our practices to create a culture of safety in psychedelic therapy. …
FOR IMMEDIATE RELEASE Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions Donation is from atai Impact, the philanthropic arm of mental …
Patient Bills of Rights are made available to patients in various settings across the mental health and medical fields to communicate clearly with patients about what they can expect from professionals …
Download this entire issue (Large Size / Reduced Size) or browse individual articles by title below. About the Cover Artist, Catherine Nelson Psychedelic Science From the Desk of Rick Doblin, Ph.D. Rick …
Written by Mitchell Gomez MAPS Bulletin 2021, Volume 31, No. 3 Editor’s note: This article is slated for publication in the upcoming issue of the MAPS Bulletin. We have elected to publish it today, …
MAPS is honored to announce the election of Carl L. Hart, Ph.D., to MAPS’ Board of Directors, effective as of October 22, 2021. to MAPS’ Board of Directors, effective as of October 22, 2021. Dr. Carl …
After 31 years since MAPS first tried to start research into MDMA-assisted therapy for PTSD inside the Veterans Affairs (VA) system, the first study participant has been enrolled in an investigator-initiated …
On October 4, 2021, Dr. Anne Wagner and a team of researchers at Remedy Institute in Toronto, Ontario, Canada, began studying MDMA-assisted cognitive processing therapy (CPT) for individuals with posttraumatic …
